Literature DB >> 33584104

Self-assembled Viral Nanoparticles as Targeted Anticancer Vehicles.

Yuanzheng Wu1, Jishun Li1, Hyun-Jae Shin2.   

Abstract

Viral nanoparticles (VNPs) comprise a variety of mammalian viruses, plant viruses, and bacteriophages, that have been adopted as building blocks and supra-molecular templates in nanotechnology. VNPs demonstrate the dynamic, monodisperse, polyvalent, and symmetrical architectures which represent examples of such biological templates. These programmable scaffolds have been exploited for genetic and chemical manipulation for displaying of targeted moieties together with encapsulation of various payloads for diagnosis or therapeutic intervention. The drug delivery system based on VNPs offer diverse advantages over synthetic nanoparticles, including biocompatibility, biodegradability, water solubility, and high uptake capability. Here we summarize the recent progress of VNPs especially as targeted anticancer vehicles from the encapsulation and surface modification mechanisms, involved viruses and VNPs, to their application potentials. © The Korean Society for Biotechnology and Bioengineering and Springer 2021.

Entities:  

Keywords:  anticancer; drug delivery; nanotechnology; self-assembly; viral nanoparticles (VNPs)

Year:  2021        PMID: 33584104      PMCID: PMC7872722          DOI: 10.1007/s12257-020-0383-0

Source DB:  PubMed          Journal:  Biotechnol Bioprocess Eng        ISSN: 1226-8372            Impact factor:   2.836


  137 in total

1.  Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

Authors:  T Todo; R L Martuza; S D Rabkin; P A Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 2.  The art of engineering viral nanoparticles.

Authors:  Jonathan K Pokorski; Nicole F Steinmetz
Journal:  Mol Pharm       Date:  2010-12-17       Impact factor: 4.939

3.  Self-assembly approaches to nanomaterial encapsulation in viral protein cages.

Authors:  Stella E Aniagyei; Christopher Dufort; C Cheng Kao; Bogdan Dragnea
Journal:  J Mater Chem       Date:  2008-01-01

4.  Rational design of cancer-targeted BSA protein nanoparticles as radiosensitizer to overcome cancer radioresistance.

Authors:  Yanyu Huang; Yi Luo; Wenjie Zheng; Tianfeng Chen
Journal:  ACS Appl Mater Interfaces       Date:  2014-10-29       Impact factor: 9.229

5.  Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture.

Authors:  Michelle L Flenniken; Lars O Liepold; Bridgid E Crowley; Deborah A Willits; Mark J Young; Trevor Douglas
Journal:  Chem Commun (Camb)       Date:  2004-12-02       Impact factor: 6.222

Review 6.  Use of plant viruses and virus-like particles for the creation of novel vaccines.

Authors:  Ina Balke; Andris Zeltins
Journal:  Adv Drug Deliv Rev       Date:  2018-08-30       Impact factor: 15.470

Review 7.  Applications of viral nanoparticles in medicine.

Authors:  Ibrahim Yildiz; Sourabh Shukla; Nicole F Steinmetz
Journal:  Curr Opin Biotechnol       Date:  2011-05-16       Impact factor: 9.740

Review 8.  Gene therapy progress and prospects cancer: oncolytic viruses.

Authors:  T-C Liu; D Kirn
Journal:  Gene Ther       Date:  2008-04-17       Impact factor: 5.250

Review 9.  Virus-like particles for vaccination against cancer.

Authors:  Mona O Mohsen; Daniel E Speiser; Alexander Knuth; Martin F Bachmann
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-08-27

10.  Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control.

Authors:  Markus Schmid; Patrick Ernst; Annemarie Honegger; Maarit Suomalainen; Martina Zimmermann; Lukas Braun; Sarah Stauffer; Cristian Thom; Birgit Dreier; Matthias Eibauer; Anja Kipar; Viola Vogel; Urs F Greber; Ohad Medalia; Andreas Plückthun
Journal:  Nat Commun       Date:  2018-01-31       Impact factor: 14.919

View more
  2 in total

Review 1.  Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials.

Authors:  Zabihollah Shoja; Somayeh Jalilvand; Tayebeh Latifi; Farzin Roohvand
Journal:  Arch Virol       Date:  2022-03-15       Impact factor: 2.685

2.  Development of 68Ga-Labeled Hepatitis E Virus Nanoparticles for Targeted Drug Delivery and Diagnostics with PET.

Authors:  Elisavet Lambidis; Chun-Chieh Chen; Mo Baikoghli; Surachet Imlimthan; You Cheng Khng; Mirkka Sarparanta; R Holland Cheng; Anu J Airaksinen
Journal:  Mol Pharm       Date:  2022-07-20       Impact factor: 5.364

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.